By and large, outcomes of our experimental inhibition of MAPK in organoids agreed with known relationships between predictive mutations and therapy sensitivity, as EGFR inhibition was only effective in RAS/RAF‐wild‐type organoids, while a combination of BRAF and EGFR inhibitors—but not each inhibitor alone—had profound effects on development of BRAFV600E‐mutant CRC organoids. Here, BRAF is linked to colorectal carcinoma.